Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04673617
Title AB-101 as Monotherapy and In Combination With Rituximab in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Artiva Biotherapeutics, Inc.

non-Hodgkin lymphoma


AB-101 + Rituximab

Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.